Samsung Biologics Achieves Record Half-Year Operating Profit Surpassing 1 Trillion Won (Comprehensive)
Q2 Sales Up 30% Year-on-Year
Operating Profit Surges 23% Over Same Period
All Eyes on H2 Earnings as Strike Impact Looms
Samsung Biologics has reported strong results, achieving an operating profit of more than 1 trillion won in just half a year. Despite the effects of a labor strike, the company posted solid results; however, attention is now shifting to the direction of its performance in the second half of the year, as the impact of union strikes, such as batch (batch·production unit) losses, will be fully reflected in future results.
On July 23, Samsung Biologics announced via a public disclosure that its sales for the second quarter reached 1.3209 trillion won, with operating profit at 586.4 billion won. Compared to the same period last year, sales increased by 30% (approximately 306.7 billion won), and operating profit rose by 23% (approximately 109.2 billion won). The company attributed this strong growth to the full operation of Factories 1 through 4 at the Incheon Songdo Campus and favorable exchange rates. As a result, the company's operating profit for the first half of this year amounted to 1.1672 trillion won, a 28.6% increase over the same period last year (907.4 billion won). This marks the first time since its founding that Samsung Biologics has posted operating profit surpassing 1 trillion won in a half-year period.
Despite the fact that pre-operating expenses for Factory 5 and the production facility in Rockville, U.S., were recognized before full-scale revenue recognition, the company maintained an operating margin in the 40% range. Samsung Biologics expects it will likely reach the upper end of its annual sales growth guidance this year.
The main concern is the continued impact of the strike. The company estimates that the partial and full-scale labor strikes that took place between April and May resulted in losses exceeding 150 billion won, and this impact is likely to be reflected in the third quarter's results. Biopharmaceuticals produced by Samsung Biologics must be discarded if manufacturing disruptions such as strikes lead to compromised data reliability.
Nevertheless, Samsung Biologics continues its efforts to secure future growth engines. A prime example is its recent decision to acquire Polypeptide Group, a global peptide CDMO (Contract Development and Manufacturing Organization).
With demand for Glucagon-Like Peptide (GLP)-1 class therapeutics surging and the need for peptide active pharmaceutical ingredient production rapidly increasing, Samsung Biologics is expediting its market entry by acquiring Polypeptide Group, a company with technical expertise, an established customer base, and commercial-scale manufacturing experience. In addition to its mainstay antibody therapeutics, the company is securing development and manufacturing capabilities for new modalities (therapeutic approaches), including messenger RNA (mRNA), antibody-drug conjugates (ADC), and now peptides.
Samsung Biologics continues its order intake activities across all areas of contract manufacturing (CMO) and contract development (CDO). Since its founding, the company has received 115 CMO and 176 CDO cumulative orders, with total cumulative order value reaching 21.7 billion USD (about 32.0943 trillion won).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
In terms of global business presence, Samsung Biologics plans to open a European sales office in the Netherlands in the third quarter of this year to accelerate its global market expansion. Following the establishment of sales offices in New Jersey, U.S. in 2023 and Tokyo, Japan last year, this expansion into Amsterdam, Netherlands in 2024 will give Samsung Biologics business hubs across the world's three main biopharmaceutical markets: the U.S., Europe, and Japan, as well as the Asia-Pacific (APAC) region. Building on this, the company aims to strengthen its order intake competitiveness and continually expand its 'super-gap' competitive advantage by enlarging its global network.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.